Sumitomo Mitsui Trust Holdings, Inc. Halozyme Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $168 Billion
- Q3 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 4,400 shares of HALO stock, worth $286,836. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,400Holding current value
$286,836% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
631Shares Held
127MCall Options Held
408KPut Options Held
384K-
Black Rock Inc. New York, NY17.6MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$798 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$387 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$226 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$221 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.08B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...